Pruritus - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pruritus - Pipeline Review, H1 2016', provides an overview of the Pruritus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pruritus - The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects - The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pruritus Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pruritus - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Pruritus Overview 10 Therapeutics Development 11 Pipeline Products for Pruritus - Overview 11 Pipeline Products for Pruritus - Comparative Analysis 12 Pruritus - Therapeutics under Development by Companies 13 Pruritus - Therapeutics under Investigation by Universities/Institutes 15 Pruritus - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Pruritus - Products under Development by Companies 19 Pruritus - Products under Investigation by Universities/Institutes 21 Pruritus - Companies Involved in Therapeutics Development 22 AlbireoPharma 22 Amorepacific Corporation 23 Cara Therapeutics, Inc. 24 Chugai Pharmaceutical Co., Ltd. 25 Creabilis SA 26 ELORAC, Inc. 27 Faes Farma, SA 28 GlaxoSmithKline Plc 29 Hydra Biosciences, Inc. 30 LEO Pharma A/S 31 Merck & Co., Inc. 32 NeRRe Therapeutics Ltd 33 Nippon Shinyaku Co., Ltd. 34 Patara Pharma, Inc. 35 Phosphagenics Limited 36 RDD Pharma Ltd. 37 Sanwa Kagaku Kenkyusho Co., Ltd. 38 Shionogi & Co., Ltd. 39 Sumitomo Dainippon Pharma Co., Ltd. 40 Tioga Pharmaceuticals, Inc. 41 Trevi Therapeutics, Inc. 42 Vanda Pharmaceuticals Inc. 43 Pruritus - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 A-4250 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 aprepitant - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 asimadoline - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ASN-008 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 bilastine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 C-745 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CR-845 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 cromolyn sodium - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CT-327 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 CT-340 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 desloratadine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 GSK-2330672 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 lidocaine hydrochloride - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 nalbuphine hydrochloride ER - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 naloxone hydrochloride - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 nemolizumab - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 NS-141 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 orvepitant maleate - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PAC-14028 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Peptides to Target TRPV1 for Pain and Itch - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 RDD-1609 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 serlopitant - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SK-1405 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule to Agonize CB2 for Pruritus - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecule to Inhibit Substance P for Pruritus - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecules to Inhibit Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 tradipitant - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Pruritus - Recent Pipeline Updates 92 Pruritus - Dormant Projects 106 Pruritus - Discontinued Products 107 Pruritus - Product Development Milestones 108 Featured News & Press Releases 108 Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting 108 Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference 109 Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain 109 Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis 109 May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845 110 Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids 111 Mar 19, 2015: Creabilis' CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 111 Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 112 Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration 113 Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients 114 Appendix 116 Methodology 116 Coverage 116 Secondary Research 116 Primary Research 116 Expert Panel Validation 116 Contact Us 116 Disclaimer 117
List of Tables
Number of Products under Development for Pruritus, H1 2016 11 Number of Products under Development for Pruritus - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Pruritus - Pipeline by AlbireoPharma, H1 2016 22 Pruritus - Pipeline by Amorepacific Corporation, H1 2016 23 Pruritus - Pipeline by Cara Therapeutics, Inc., H1 2016 24 Pruritus - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 25 Pruritus - Pipeline by Creabilis SA, H1 2016 26 Pruritus - Pipeline by ELORAC, Inc., H1 2016 27 Pruritus - Pipeline by Faes Farma, SA, H1 2016 28 Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2016 29 Pruritus - Pipeline by Hydra Biosciences, Inc., H1 2016 30 Pruritus - Pipeline by LEO Pharma A/S, H1 2016 31 Pruritus - Pipeline by Merck & Co., Inc., H1 2016 32 Pruritus - Pipeline by NeRRe Therapeutics Ltd, H1 2016 33 Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 34 Pruritus - Pipeline by Patara Pharma, Inc., H1 2016 35 Pruritus - Pipeline by Phosphagenics Limited, H1 2016 36 Pruritus - Pipeline by RDD Pharma Ltd., H1 2016 37 Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 38 Pruritus - Pipeline by Shionogi & Co., Ltd., H1 2016 39 Pruritus - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 40 Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H1 2016 41 Pruritus - Pipeline by Trevi Therapeutics, Inc., H1 2016 42 Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 43 Assessment by Monotherapy Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 48 Number of Products by Stage and Route of Administration, H1 2016 50 Number of Products by Stage and Molecule Type, H1 2016 52 Pruritus Therapeutics - Recent Pipeline Updates, H1 2016 92 Pruritus - Dormant Projects, H1 2016 106 Pruritus - Discontinued Products, H1 2016 107
List of Figures
Number of Products under Development for Pruritus, H1 2016 11 Number of Products under Development for Pruritus - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 44 Number of Products by Top 10 Targets, H1 2016 45 Number of Products by Stage and Top 10 Targets, H1 2016 45 Number of Products by Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Routes of Administration, H1 2016 49 Number of Products by Stage and Routes of Administration, H1 2016 49 Number of Products by Molecule Types, H1 2016 51 Number of Products by Stage and Molecule Types, H1 2016 51
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.